Pmd60 - Developing a Comprehensive Treatment Cost Comparison Model in Guillain-Barre Syndrome and Myasthenia Gravis to Compare the Total Cost of Ivig Based Treatment Versus Centrifugal Therapeutic Plasma Exchange

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1509
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pmd59 - Developing a Comprehensive Treatment Cost Comparison Model in Sickle Cell Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Intravenous Immunoglobulins Versus Plasma Exchange in the Treatment of Guillain-Barré Syndrome

Critical Care
Critical CareIntensive Care Medicine
2009English

Guillain-Barré Syndrome: Surveillance and Cost of Treatment Strategies

The Lancet
Medicine
2017English

Effect of Therapeutic Plasma Exchange on Immunoglobulins in Myasthenia Gravis

Autoimmunity
AllergyImmunology
2016English

Advances in the Diagnosis and Treatment of Guillain-Barre Syndrome

Journal of the Neurological Sciences
Neurology
2015English

Intravenous Immune Globulins in Patients With Guillain-Barre Syndrome and Contraindications to Plasma Exchange: 3 Days Versus 6 Days

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2001English

Cost-Effectiveness Analysis of 10% Intravenous Immunoglobulin Compared With Plasma Exchange in Treatment of Children With Guillain–Barré Syndrome in Russia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

The Use of IVIg in the Treatment of Inflammatory Polyneuropathies and Myasthenia Gravis at the Walton Centre

Journal of the Royal College of Physicians of Edinburgh, The
MedicineEducationHistory
2019English

Occurrence of Guillain-Barré Syndrome and Myasthenia Gravis in an Elderly Male

Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Mental HealthPsychiatric Mental HealthNeurologyPsychiatryNeuroscienceSurgery
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy